ANTHEM935.35

Anthem Biosciences Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSYNGENEDIVISLABGLAXOAJANTPHARMIPCALABABBOTINDIAMEDANTAGLENMARKMcap ₹52,540 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations2,124.32,002.3
Other Income155.8157.9
Total Income2,280.12,160.2
Expenses
+ Cost of Materials Consumed713.6700.0
+ Changes in Inventories98.727.7
+ Employee Benefit Expense282.7289.5
+ Finance Costs6.96.2
+ Depreciation & Amortisation134.1137.6
+ Other Expenses195.5192.3
Total Expenses1,431.51,353.2
EBITDA833.8792.9
EBIT699.7655.3
Profit
PBT before Exceptional Items848.6807.0
+ Exceptional Items-24.4-24.4
Pretax Income824.2782.6
+ Current Tax241.3225.9
+ Deferred Tax-8.9-19.3
Tax Expense232.4206.6
Net Income591.8575.9
+ Net Income — Continuing Ops591.8575.9
+ Other Comprehensive Income-1.6-2.2
Total Comprehensive Income590.2573.8
Per Share
Basic EPS0.006.87
Diluted EPS0.006.81
Other Comprehensive Income — detail
+ Other Comprehensive Income-1.6-2.2
+ Items NOT to be Reclassified to P&L-1.6-2.4
+ Tax on Items NOT to be Reclassified0.0-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations0.006.87
Diluted EPS — Continuing Operations0.006.81
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,312.11,274.7
Gross Margin %61.7663.66
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)848.6807.0
− Exceptional Items (reconciliation)-24.4-24.4
Net Income Adj (tax-effected)609.3593.9
EPS Adj0.007.08
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.00
Filed Debt Equity0.01
Filed Dscr0.29
Filed Iscr1.64
Paid Up Equity Capital112.3112.7
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.